However, the resistance to imatinib may develop in significant portions of patients under treatment, especially in those with CML in advanced stages or with Ph+ ALL mostly due to the emergence of mutations in the BCR/ABL kinase domain, including the most prevalent E255K and T315I mutations. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.